12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CB-315: Phase III started

Cubist began the first of a pair of identical, double-blind, international Phase III trials to compare 250 mg twice-daily CB-315 vs. 125...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >